Class A Chinese cancer centres offer remote second opinions for USD 800–1,800 with a 7–10 business-day turnaround — high-leverage when the home recommendation feels rushed, ambiguous, or unaffordable.
A formal second opinion from a Class A Chinese cancer centre is most useful when (a) the home recommendation is ambiguous or stage-borderline, (b) the proposed treatment is expensive enough that being wrong has a major financial consequence, or (c) the disease is rare. Cost is USD 800–1,800 for a written multi-disciplinary review delivered in 7–10 business days . For patients who ultimately travel for treatment, the second-opinion fee is typically applied as a credit to the treatment cost.
The Short Answer
A formal second opinion from a Class A Chinese cancer centre is most useful when (a) the home recommendation is ambiguous or stage-borderline, (b) the proposed treatment is expensive enough that being wrong has a major financial consequence, or (c) the disease is rare. Cost is USD 800–1,800 for a written multi-disciplinary review delivered in 7–10 business days. For patients who ultimately travel for treatment, the second-opinion fee is typically applied as a credit to the treatment cost.
When a Second Opinion Changes the Plan
Published data from major US cancer centres (Mayo Clinic, MSKCC) shows that 10–20% of second opinions change the diagnosis and 30–40% change the treatment recommendation — most often refining stage, refining systemic therapy choice, or identifying a clinical trial. The yield is highest for:
- Rare tumours — sarcoma, NET, rare head-and-neck histology.
- Stage-borderline cases — early-stage with high-risk features; oligometastatic.
- Treatment-intent disputes — surgery vs radiation vs combined.
- Genomic-guided therapy decisions — when molecular results suggest a non-obvious targeted option.
Cancer Centres With Mature International Second-Opinion Programmes
- Sun Yat-sen University Cancer Centre (SYSUCC, Guangzhou) — China's top cancer-only centre.
- CAMS Cancer Hospital (National Cancer Centre, Beijing) — proton therapy and integrative oncology.
- Fudan University Shanghai Cancer Centre — strong breast, GI, lung programmes.
- Peking University Cancer Hospital — breast oncology, gastric cancer.
- West China Hospital — integrative oncology and lung cancer.
What You'll Send
- Pathology report and slides (digital scans or physical glass slides for re-review).
- All staging imaging in DICOM format (CT, MRI, PET).
- Genomic / molecular reports (NGS panel, IHC, FISH).
- Treatment history including all systemic and radiation therapy.
- Most recent two oncologist consultation letters.
- One specific question for the Chinese team (e.g., "Is concurrent chemo-radiation or sequential the right path?").
What You'll Get Back
A 5–8 page written multi-disciplinary review covering:
- Pathology re-review with comments on accuracy of stage and grade.
- Imaging re-read by a tumour-board radiologist.
- Recommended treatment pathway with rationale.
- Notable clinical-trial options including any Chinese-only studies.
- Direct answer to your specific question.
For complex cases, a video consultation with the Chinese tumour board can be added (USD 400–700 supplemental).
How to Decide Whether to Travel
About 40% of international second-opinion cases result in the patient travelling to China for treatment — most commonly when:
- The recommended therapy is proton therapy or another high-cost option (China cost is 1/3 to 1/5 of US).
- The recommended therapy is an early-phase clinical trial accessible in China.
- The home insurer doesn't cover the proposed treatment.
- The patient values consolidating diagnosis and treatment in one programme.
The other 60% return to their home oncologist with a refined plan and stay home for treatment — also a legitimate outcome.
To start a written second opinion, use the quote wizard and select "Cancer second opinion". For our dedicated cancer-pathway page, see cancer second opinion in China.
Sources: Mayo Clinic and Memorial Sloan Kettering published second-opinion outcomes data; CSCO oncology second-opinion programme guidelines; partner-network 2026 second-opinion case-volume data.